The Global Pharmaceutical Market Forecast

Market Overview The global pharmaceutical market is a multi-billion dollar industry. Ten large pharmaceutical companies manage more than one-third of the market, annual turnover is over $ 1 billion, profit margin is 30%. Six of these companies are in the US and four are in Europe. North America, South America, Europe, Japan are predicted to continue to occupy 85% of the global pharmaceutical market. Today, the company spends about a third of all sales in marketing, which is about twice the amount spent on research and development (the "pharmaceutical industry").

Last year, the global pharmaceutical industry reached a record high of about 1.11 trillion dollars, and the industry is expected to increase to 1.43 trillion dollars by 2020. Along with the increase in worldwide demand for pharmaceutical products, these biotechnology companies are working 24 hours a day, and we hope to introduce the next big country drugs to the market. GT Biopharma focuses on Tri-and Tetra-specific killer attackers (TriKE) and (TetraKE) based on proprietary platform and bispecific antibody drug conjugate (ADC) for acute lymphocytes, He specializes in the development of tumor therapy. Innovative treatment for leukemia, non-Hodgkin's lymphoma, acute myeloid leukemia and multiple solid tumors. The GTBP pipeline consists of seven candidates for phase II trials or preclinical trials.

The Chinese pharmaceutical market is now the second largest pharmaceutical market in the world and its value in 2014 is US $ 105 billion. It is expected to increase significantly by 2020 to US $ 200 billion and further increase its position as a leading Asian company. By 2020, more than 260 million Chinese are predicted to be over the age of 60, which will lead to a surge in demand for medical and medical services. The US is still the world leader in science and engineering expenses, accounting for 27% of R & D expenses worldwide. However, China is not late, accounting for 20%. Kelvin Droegemeier, Deputy Chairman of the National Science Council, says: Between 2003 and 2013, investment in R & D in China has increased significantly, with annual average growth rate of 19.5%.

China's pharmaceutical industry is expected to further slow down in 2016, but China is still the fastest growing market for the world pharmaceutical industry and continues to invest heavily in research and development. Due to slowing economic growth in China and new government regulations, the current situation is fickle, but if you are cautious it will be risky.